Ziltivekimab

Ziltivekimab is a fully human monoclonal antibody against interleukin 6. It is developed by Novo Nordisk to treat heart failure. In clinical trials, levels of high-sensitivity C-reactive protein were reduced in people taking the drug. The drug has also been tested in chronic kidney disease.